Activity of Low Dose Nivolumab in Patients With Advanced Squamous Cell Carcinomas and Other Cancers. (PubMed, Int J Cancer) - Oct 21, 2026 - "Low-dose nivolumab demonstrates encouraging efficacy and tolerability in a frail population, supporting its potential role in resource-limited settings. Prospective trials are warranted to confirm these findings in broader populations."
Journal • Head and Neck Cancer • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer
|
|
Armelle Dufresne; Aurélie Dutour; Axel de Bernardi; Benoite Méry; Clélia Coutzac; Eve-Marie Neidhart-Berard; Isabelle Ray-Coquard; Jean-Yves Blay; Jérôme Fayette; Laura Crumbach; Margaux Dupont; Marie Castets; Mehdi Brahmi; Mona Amini-Adle; Philippe Toussaint; Pierre Etienne Heudel; Thibault Gauduchon
|